Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venglustat versus standard of care for Fabry disease with left ventricular hypertrophy
2021-002320-20Phase 3Active
- Sponsor
- Sanofi
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Fabry disease (FD) comparing Venglustat with Usual standard of care Fabry therapies (2 arms). Primary endpoint: Slope of left ventricular mass index. Started Oct 2021; status: active.
02
Drugs
venglustat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2021-002320-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002320-20.